Agents targeting CD138 and uses thereof

US9221914B2 · kind B2 · utility

Assignee

• Biotest AG · DE

Inventors

• Elmar Kraus · Bad Vilbel, DE
• Christoph Bruecher · Eschborn, DE
• Benjamin Daelken · Frankfurt am Main, DE
• Matthias Germer · Langen, DE
• Steffen Zeng · Munster, DE
• Frank Osterroth · Dietzenbach, DE
• Christoph Uherek · Seligenstadt, DE
• Silke Aigner · Bischofswerda, DE
• Gregor Schulz · Umkirch, DE

Key dates

• Filing date: Dec 23, 2008
• Grant date: Dec 29, 2015
• Expiry date: Dec 23, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed is a human murine chimeric antibody targeting CD138 which substantially retains the antigen binding region of its murine counterpart. The engineered antibody displays improved binding affinities to the antigen and/or more homogenous binding to target cells relative to its murine counterpart. A constant region of the immunoglobulin heavy chain is preferably an IgG4 isotype constant region.